Chesapeake Wealth Management acquired a new position in Becton Dickinson and Co (NYSE:BDX) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 3,960 shares of the medical instruments supplier’s stock, valued at approximately $858,000.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. Amica Retiree Medical Trust raised its position in shares of Becton Dickinson and by 325.0% during the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock valued at $109,000 after buying an additional 390 shares during the last quarter. Almanack Investment Partners LLC. bought a new stake in Becton Dickinson and in the fourth quarter worth $109,000. BDO Wealth Advisors LLC increased its position in Becton Dickinson and by 361.6% in the first quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock worth $125,000 after purchasing an additional 452 shares during the last quarter. Advisors Preferred LLC purchased a new position in Becton Dickinson and during the fourth quarter worth $126,000. Finally, Truewealth LLC purchased a new position in Becton Dickinson and during the fourth quarter worth $133,000. 84.08% of the stock is currently owned by institutional investors.
In related news, insider Alexandre Conroy sold 20,128 shares of the company’s stock in a transaction on Monday, May 21st. The stock was sold at an average price of $228.74, for a total value of $4,604,078.72. Following the completion of the transaction, the insider now directly owns 35,583 shares in the company, valued at $8,139,255.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Nabil Shabshab sold 10,209 shares of the company’s stock in a transaction dated Friday, May 11th. The stock was sold at an average price of $226.10, for a total value of $2,308,254.90. Following the sale, the executive vice president now owns 12,476 shares of the company’s stock, valued at $2,820,823.60. The disclosure for this sale can be found here. 1.00% of the stock is owned by insiders.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 3rd. The medical instruments supplier reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.02. Becton Dickinson and had a positive return on equity of 14.27% and a negative net margin of 0.46%. The business had revenue of $4.22 billion during the quarter, compared to analysts’ expectations of $4.12 billion. During the same quarter last year, the business posted $2.30 EPS. The business’s quarterly revenue was up 42.2% compared to the same quarter last year. sell-side analysts expect that Becton Dickinson and Co will post 10.99 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 29th. Investors of record on Friday, June 8th will be paid a $0.75 dividend. The ex-dividend date is Thursday, June 7th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.25%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 31.65%.
A number of analysts have recently issued reports on BDX shares. Citigroup raised shares of Becton Dickinson and from a “neutral” rating to a “buy” rating and boosted their target price for the company from $237.00 to $251.00 in a research note on Tuesday, April 10th. ValuEngine raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating in a research note on Wednesday, April 18th. Zacks Investment Research downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Tuesday, March 6th. BMO Capital Markets assumed coverage on shares of Becton Dickinson and in a report on Monday, March 5th. They set a “market perform” rating and a $249.00 price objective on the stock. Finally, JPMorgan Chase & Co. upgraded Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 target price on the stock in a research report on Thursday, June 21st. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Becton Dickinson and presently has an average rating of “Buy” and a consensus target price of $237.29.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.